Quick Takeaways
- SVA - SINOVAC BIOTECH LTD has 13 insiders with reported activity on this page.
- No net insider buy/sell flow is currently reported for the last year.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 13 Insiders of SINOVAC BIOTECH LTD
- Symbol
- SVA on Nasdaq
- Location
- Beijing
What Changed
- No meaningful buy/sell imbalance is currently visible in the one-year window.
- Activity will update as new Forms 3/4/5 are filed.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsInsider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 28 Apr 2025.
Buys
$0
Shares: 0
Insiders: 0
Sells
$0
Shares: 0
Insiders: 0
Net
$0
Shares: 0
Insiders: 0
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
SINOVAC BIOTECH LTD executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Jiaqiang Li | Director | $119,803,345 | Median | 17 Apr 2026 | ||
| Andrew Y. Yan | Director | $69,751,905 | Mixed | 18 Mar 2026 | ||
| Yin Weidong | Chief Executive Officer, Director | $41,145,965 | Mixed | 18 Mar 2026 | ||
| Fu Shan | Director | $38,192,410 | Mixed | 18 Mar 2026 | ||
| Nan Wang | Chief Financial Officer | $2,296,850 | Mixed | 18 Mar 2026 | ||
| Qiang (nmn) Gao | Chief Operation Officer | $1,488,100 | Mixed | 18 Mar 2026 | ||
| Jing (nmn) Li | VP, Quality and Production | $1,471,925 | Mixed | 18 Mar 2026 | ||
| Guang (helen) Yang | Chief Business Officer | $1,118,663 | Mixed | 18 Mar 2026 | ||
| Yuk Lam Lo | Director | $582,300 | Mixed | 18 Mar 2026 | ||
| Simon Anderson | Director | $452,900 | Mixed | 18 Mar 2026 | ||
| Yu Min Qiu | Director | Mixed | 18 Mar 2026 | |||
| Yu (nmn) Wang | Director | Mixed | 18 Mar 2026 | |||
| Shuge Jiao | Director | Mixed | 18 Mar 2026 |
Top shareholders of SINOVAC BIOTECH LTD (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Vivo Capital IX, LLC |
13D/G
|
— |
6.3%
|
4,539,456
|
$293,522,587 | $0 | 17 Mar 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
3.8%
|
2,718,735
|
$184,466,170 | — | 31 Dec 2025 | |
| Jiaqiang Li |
3/4/5
|
Director |
26%
|
18,515,315
|
$119,803,345 | — | 17 Apr 2026 | |
| Andrew Y. Yan |
3/4/5
|
Director |
15%
|
10,780,820
|
$69,751,905 | — | 18 Mar 2026 | |
| Yin Weidong |
3/4/5
13D/G
|
Chief Executive Officer, Director · Weidong Yin |
8.8%
from 13D/G
|
6,359,500
|
$41,145,965 | — | 18 Mar 2026 | |
| Fu Shan |
3/4/5
|
Director |
8.2%
|
5,903,000
|
$38,192,410 | — | 18 Mar 2026 | |
| Vivo Capital, LLC |
13F
|
Company |
8.2%
|
5,903,000
|
$38,192,410 | — | 31 Dec 2025 | |
| Nan Wang |
3/4/5
|
Chief Financial Officer |
0.49%
|
355,000
|
$2,296,850 | — | 18 Mar 2026 | |
| Neumann Advisory Hong Kong Ltd |
13F
|
Company |
0.44%
|
315,586
|
$2,042,000 | — | 31 Dec 2025 | |
| Qiang (nmn) Gao |
3/4/5
|
Chief Operation Officer |
0.32%
|
230,000
|
$1,488,100 | — | 18 Mar 2026 | |
| Jing (nmn) Li |
3/4/5
|
VP, Quality and Production |
0.32%
|
227,500
|
$1,471,925 | — | 18 Mar 2026 | |
| Guang (helen) Yang |
3/4/5
|
Chief Business Officer |
0.24%
|
172,900
|
$1,118,663 | — | 18 Mar 2026 | |
| Yuk Lam Lo |
3/4/5
|
Director |
0.13%
|
90,000
|
$582,300 | — | 18 Mar 2026 | |
| Simon Anderson |
3/4/5
|
Director |
0.1%
|
70,000
|
$452,900 | — | 18 Mar 2026 | |
| Aprio Wealth Management, LLC |
13F
|
Company |
0%
|
439
|
$284,033 | — | 31 Dec 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.02%
|
16,876
|
$109,188 | — | 31 Dec 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.02%
|
16,430
|
$106,302 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.01%
|
9,222
|
$59,666 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.01%
|
9,144
|
$59,161 | — | 31 Dec 2025 | |
| Horizon Investments, LLC |
13F
|
Company |
0%
|
52
|
$336 | — | 31 Dec 2025 | |
| 1Globe Capital LLC |
13D/G
|
— |
32%
|
18,515,315
|
— | $0 | 07 Jul 2025 | |
| SAIF Partners IV L.P. |
13D/G
|
— |
15%
|
10,780,820
|
— | $0 | 15 Dec 2025 | |
| Advantech Capital L.P. |
13D/G
|
— |
8.1%
|
5,851,423
|
— | $0 | 08 Jul 2025 | |
| Vivo Capital VIII, LLC |
13D/G
|
Vivo Capital IX, LLC |
6.3%
|
4,541,764
|
— | $0 | 11 Jul 2025 |
Recent Insider Transactions by Companies or Individuals for SINOVAC BIOTECH LTD
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Jiaqiang Li | SVA | Common shares, par value $0.001 per share | 0 | 18,515,315 | 17 Apr 2026 | By 1Globe Capital LLC, CDH Utopia Limited and the others | ||||
| Jing (nmn) Li | SVA | Common shares, par value $0.001 per share | 0 | 227,500 | 18 Mar 2026 | Direct | ||||
| Guang (helen) Yang | SVA | Common shares, par value $0.001 per share | 0 | 172,900 | 18 Mar 2026 | Direct | ||||
| Fu Shan | SVA | Common shares, par value $0.001 per share | 0 | 5,903,000 | 18 Mar 2026 | By Vivo Capital Fund VIII, L.P., Vivo Capital Surplus Fund VIII, L.P. and Vivo Capital Fund IX, L.P. | ||||
| Simon Anderson | SVA | Common shares, par value $0.001 per share | 0 | 70,000 | 18 Mar 2026 | Direct | ||||
| Yin Weidong | SVA | Common shares, par value $0.001 per share | 0 | 6,359,500 | 18 Mar 2026 | Direct | ||||
| Andrew Y. Yan | SVA | Common shares, par value $0.001 per share | 0 | 10,780,820 | 18 Mar 2026 | By SAIF Partners IV L.P. | ||||
| Qiang (nmn) Gao | SVA | Common shares, par value $0.001 per share | 0 | 230,000 | 18 Mar 2026 | Direct | ||||
| Nan Wang | SVA | Common shares, par value $0.001 per share | 0 | 355,000 | 18 Mar 2026 | Direct | ||||
| Yuk Lam Lo | SVA | Common shares, par value $0.001 per share | 0 | 90,000 | 18 Mar 2026 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.